Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,464.65 -10.44 (-0.19%) Dow
39,114.50 -55.02 (-0.14%) Nasdaq
17,829.48 -49.82 (-0.28%) Bitcoin USD
62,882.50 +15.94 (+0.03%) CMC Crypto 200
1,344.63 +0.12 (+0.01%)
Vertex Pharmaceuticals Inc (VX1.SG)
| Previous close | 438.30 |
| Open | 438.05 |
| Bid | 441.10 x 50000 |
| Ask | 443.20 x 100000 |
| Day's range | 438.05 - 441.50 |
| 52-week range | 307.15 - 450.15 |
| Volume | |
| Avg. volume | 26 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireVertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
BOSTON, July 02, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for investigational once-daily vanzacaftor/tezacaftor/deutivacaftor triple combination therapy (vanza triple) for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Business WireVertex to Announce Second Quarter 2024 Financial Results on August 1
BOSTON, July 01, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2024 financial results on Thursday, August 1, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Second Quarter 2024 Earnings Call."
- GuruFocus.com
Insider Sale at Vertex Pharmaceuticals Inc (VRTX): EVP and CMO Carmen Bozic Sells 2,280 Shares
The transaction was executed at a price of $471.72 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 30,099 shares of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a biotechnology firm focused on developing and commercializing therapies for the treatment of cystic fibrosis and other severe diseases.
